Physician profile
Michael Bennett
NPI 1700895927
$5,441.58
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $943 · 2020: $4,338 · 2021: $161.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $2,450.00 | 2020 | |
| Adare Pharmaceuticals, INC. | $1,121.67 | 2020 | |
| Novartis Pharmaceuticals Corporation | $590.49 | 2020 | |
| Abbvie INC. | $352.06 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $252.57 | 2019-2021 | |
| Gilead Sciences, INC. | $151.55 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $139.28 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.80 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $61.87 | 2019 | |
| Shionogi INC | $53.20 | 2019 | |
| Ucb, INC. | $27.00 | 2019 | |
| Allergan, INC. | $23.91 | 2019 | |
| Amag Pharmaceuticals, INC. | $22.96 | 2019 | |
| Ironwood Pharmaceuticals, INC | $22.45 | 2019 | |
| Braintree Laboratories, INC. | $21.35 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $19.59 | 2020 | |
| Merck Sharp & Dohme LLC | $18.82 | 2019 | |
| Pfizer INC. | $17.93 | 2019 | |
| Qol Medical, LLC | $16.08 | 2019 |
2 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.